Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Franciaország3. fázis

Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)

A legfontosabb adatok

Ki végzi
Assistance Publique Hopitaux De Marseille
Hol
Marseille (Franciaország)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
110 fő, tervezett
Kezdés
2023. febr. 3.
Várható befejezés
2033. okt. 3.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • treatment Vincristin
  • treatment Actinomycin-D
  • treatment Doxorubicin
  • treatment Carboplatin
  • Etoposide
A regiszteradat frissítve
2025. április 8.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan gyerekeket és fiatalokat keres, legfeljebb 17 évesek, akiknek a vesedaganata már az első felismerésekor áttétet adott a szervezet más részeire.

Életkor
Legfeljebb 17 év
Nem
Minden nem csatlakozhat
A betegség stádiuma
Vesedaganat, amely már az első diagnózisnál áttétet adott, legalább egy kerek, meszesedés nélküli, 3 mm-es vagy nagyobb göbbel a tüdőben (vagy más, áttétre erősen gyanús elváltozással) a CT-vizsgálaton, és az áttétet központi felülvizsgálat megerősíti

A regiszter feltételei, szó szerint

Mind a 4 feltétel megnézéseKevesebb

Ki vehet részt

  • suffering from metastatic renal tumour at initial diagnosis
  • having at least one circumscript, non-calcified (pulmonary) nodule (or other lesion highly suspicious of metastasis according to criteria for metastatic disease) ≥ 3 mm as determined by chest CT-scan and abdominal CT-scan/MRI
  • Metastatic disease must be confirmed by central review

Ki nem vehet részt

  • -

Ez a vizsgálat jelenleg itt érhető el: Franciaország.

  • Assistance Publique Hôpitaux de MarseilleMarseille, FranciaországContact: ARNAULD VERSCHUURRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Nephroblastoma (Wilms tumor, WT) is the most common renal tumor of childhood representing ± 6% of all childhood malignancies. The diagnosis is established on clinical and radiological grounds. Metastases are visible on conventional imaging in at least 12% of nephroblastoma patients; however, an additional ~15% of patients have nodules on CT-scan only. The treatment consists of neoadjuvant (preoperative) chemotherapy, nephrectomy and risk-based adjuvant chemotherapy ± radiation therapy (RT) to the flank and/or metastases. For truly localized tumors, overall survival is > 85% (high risk histology excluded). Several high risk biological characteristics have been identified: diffuse anaplasia, gain of 1q chromosome, loss of heterozygosity 1p + 16q, blastemal residual volume.

A teljes eredeti leírásKevesebb

For metastatic nephroblastoma, the standard neo-adjuvant chemotherapy includes 3 drugs: vincristine, actinomycin-D and doxorubicin (VAD). Long-term survival is 82% (1). However, two issues arise. First, the use of doxorubicin ± concomitant RT might be associated with cardiac and pulmonary sequelae (4-17% of congestive heart failure) (2), and actinomycin-D is associated with hepatic toxicity (3). Second, patients with "CT-only" nodules are treated according to "localized disease". However, their outcome is poorer than that of truly "localized disease" (4-6).

The efficacy of carboplatin and etoposide is known for a long time; these drugs are used as second line treatment or for high-risk histology nephroblastoma. Therefore, an alternate chemotherapy has been designed that combines drugs shown as highly efficacious in nephroblastoma, i.e., Vincristine, Carboplatin and Etoposide (VCE). VCE has been used for the treatment of other pediatric malignancies. For metastatic nephroblastoma, the switch from VAD to VCE and the associated reduction of actinomycin-D and doxorubicin is expected to reduce the chemotherapy-related long-term toxicity. In addition, VCE could potentially decrease the rate of patients requiring pulmonary RT. Finally VCE may have a beneficial effect on tumor high risk biological characteristics.

French patients with nephroblastoma have been treated for > 40 years according to SIOP protocols collaborating in the SIOP Renal Tumour Study Group (SIOP-RTSG). This group has designed an international randomized phase III clinical trial for the evaluation of VCE versus VAD in patients with metastatic renal tumors (>>90% having nephroblastoma), in order to decrease the long-term toxicity while at least preserving, if not improving, the treatment efficacy. In addition, the issue of "CT-only" nodules and their adequate treatment needs to be solved. In previous protocols, the treatment strategy was based on the diagnosis of pulmonary metastases (~90% of all metastases) by conventional pulmonary X-ray. Central Radiological Review (CRR) is planned for the initial staging using CT ± MRI, as it is expected to more accurately detect patients with metastatic disease, including patients with "CT-only" nodules. In addition, CRR will be set up for real-time response assessment during treatment, in order to reliably determine who require pulmonary RT and which postoperative chemotherapy.

Therefore, the main trial objectives are:

* Explore the non-inferiority (efficacy) of neoadjuvant VCE chemotherapy (experimental arm) as compared to the standard arm with VAD. * Provide central radiological review (CRR) at diagnosis and after neoadjuvant chemotherapy in order to determine more precisely the appropriate treatment for each patient.

The primary objective of the RCT is to investigate the metastatic complete response rate (MetCR, including very good partial response (VGPR)) of neoadjuvant 6 weeks of VAD as compared to neoadjuvant VCE in stage IV renal tumours using CRR. Several international studies have shown that MetCR is a good surrogate endpoint for survival.

The postoperative treatment, secondary objectives as well as the intended methodology are detailed in the research project.

The total number of patients is 406 patients for the entire phase III trial running in the 12 major SIOP countries (max 110 patients in France).

The expected trial duration is 5 years for accrual + 2 years follow-up (the overall 10-year follow-up for long-term toxicity will be an independently funded ancillary study. This duration is required for a reliable evaluation of the cardiac toxicity).

The results of the current trial should be useful for the future protocols for the treatment of all patients with nephroblastoma (metastatic but also localized and bilateral).

The results of this RCT will be worthy for the entire international pediatric oncology community and future patients throughout the world and will be communicated in scientific congresses and high-level peer-reviewed journals.

A vizsgálat 2 csoportja

  • treatment VADMár használt kezelés, összehasonlításként

    Vincristin, Actinomycin-D and Doxorubicin

    Kezelés: treatment Vincristin, treatment Actinomycin-D és treatment Doxorubicin

  • treatment VCEA vizsgált kezelés

    Vincristin, Carboplatin and Etoposide

    Kezelés: treatment Vincristin, treatment Carboplatin és Etoposide

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Randomized Open-label Non-inferiority Phase 3 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
A regiszteradat frissítve
2025. április 8.